CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) |
Total |
Ordinary shares |
Reserves |
Accumulated Deficit |
Accumulated Other Comprehensive Income (Loss) |
Total Stockholders' Equity (Virax) |
Non Controlling Interest |
|---|---|---|---|---|---|---|---|
| Number of shares, beginning balance at Mar. 31, 2023 | 62,189 | ||||||
| Equity, beginning balance at Mar. 31, 2023 | $ 8,904,013 | $ 1,555 | $ 20,921,005 | $ (11,794,460) | $ (1,688) | $ 9,126,412 | $ (222,399) |
| Pre-funded warrant exercise, shares | 9,374 | ||||||
| Pre-funded warrant exercise | 234 | $ 234 | 234 | ||||
| Warrant exercise, shares | 29,363 | ||||||
| Warrant exercise | 1,872,506 | $ 734 | 1,871,772 | 1,872,506 | |||
| Shares issued for settlement of debt, shares | 900 | ||||||
| Shares issued for settlement of debt | 85,502 | $ 23 | 85,479 | 85,502 | |||
| Shares issued for rounding on Share Consolidation, shares | 1,131 | ||||||
| Shares issued for rounding on Share Consolidation | 28 | $ 28 | 28 | ||||
| Stock-based compensation | 1,011,973 | 1,011,973 | 1,011,973 | ||||
| Foreign currency adjustment | 3,639 | 3,639 | 3,639 | ||||
| Net Loss | (6,739,120) | (6,733,537) | (6,733,537) | (5,583) | |||
| Number of shares, ending balance at Mar. 31, 2024 | 102,957 | ||||||
| Equity, ending balance at Mar. 31, 2024 | 5,138,775 | $ 2,574 | 23,890,229 | (18,527,997) | 1,951 | 5,366,757 | (227,982) |
| Shares issued for cash, shares | 59,997 | ||||||
| Shares issued for cash | 5,128,186 | $ 1,500 | 5,126,686 | 5,128,186 | |||
| Warrant exercise, shares | 10,725 | ||||||
| Warrant exercise | 786,736 | $ 268 | 786,468 | 786,736 | |||
| Stock-based compensation | 365,309 | 365,309 | 365,309 | ||||
| Foreign currency adjustment | 110,379 | 110,379 | 110,379 | ||||
| Net Loss | $ (6,067,232) | (6,061,247) | (6,061,247) | (5,985) | |||
| Number of shares, ending balance at Mar. 31, 2025 | 173,679 | 173,679 | |||||
| Equity, ending balance at Mar. 31, 2025 | $ 5,462,153 | $ 4,342 | 30,168,692 | (24,589,244) | 112,330 | 5,696,120 | (233,967) |
| Shares issued for cash, shares | 123,259 | ||||||
| Shares issued for cash | 2,782,707 | $ 3,081 | 2,779,626 | 2,782,707 | |||
| PIPE transaction | 4,413,758 | 4,413,758 | 4,413,758 | ||||
| Pre-funded warrant exercise, shares | 282,280 | ||||||
| Pre-funded warrant exercise | 705 | $ 7,057 | (6,352) | 705 | |||
| Stock-based compensation | 130,409 | 130,409 | 130,409 | ||||
| Foreign currency adjustment | (422,608) | (422,608) | (422,608) | ||||
| Net Loss | $ (5,032,184) | (5,023,750) | (5,023,750) | (8,434) | |||
| Number of shares, ending balance at Mar. 31, 2026 | 579,218 | 579,218 | |||||
| Equity, ending balance at Mar. 31, 2026 | $ 7,334,940 | $ 14,480 | $ 37,486,133 | $ (29,612,994) | $ (310,278) | $ 7,577,341 | $ (242,401) |